Results of exploratory analysis of overall survival data from the pivotal phase III IMpower010 study were presented on the ground…
Researchers at the Vall d’Hebron Institute of Oncology (VHIO), part of the Vall d’Hebron Campus, have found that breast milk…
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease that represents about 15% of breast cancer cases. Classified as…
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
An International Workgroup of Cancer Genetics Experts Convened by the American College of Medical Genetics and Genomics Develops Guidance on…
Published in the journal Clinical Cancer Research (1), preliminary results of a two-part, phase I first-in-human study show encouraging antitumor…
Mutations in the TP53 tumor suppressor gene occur in 50% of lung adenocarcinoma and associate with a poor prognosis, but…
Published in The Lancet Oncology (1) and co-authored by VHIO’s Cristina Suarez, results from the single-arm phase II KEYNOTE-B61 clinical…
We are delighted to announce that VHIO’s Rodrigo Dienstmann has been appointed as Editor-in-Chief of the European Society for Medical…
Recently published open access in the journal Nature Communications*, an invited Comment article first authored by VHIO’s Elena Garralda, sets…
The Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials, PRIME-ROSE project, which counts on VHIO’s participation, launched on July…
Blood-based circulating tumor DNA analysis of plasma samples from patients enrolled in the open-label, randomized phase III VOYAGER clinical trial…
